Research ExplorerPublicationsAssessment of Health-Related Quality of Life in Patients wit...

Assessment of Health-Related Quality of Life in Patients with Advanced Prostate Cancer-Current State and Future Perspectives

Standard

Assessment of Health-Related Quality of Life in Patients with Advanced Prostate Cancer-Current State and Future Perspectives. / Kretschmer, Alexander; van den Bergh, Roderick C N; Martini, Alberto; Marra, Giancarlo; Valerio, Massimo; Tsaur, Igor; Heidegger, Isabel; Kasivisvanathan, Veeru; Kesch, Claudia; Preisser, Felix; Fankhauser, Christian D; Zattoni, Fabio; Ceci, Francesco; Olivier, Jonathan; Chiu, Peter; Puche-Sanz, Ignacio; Thibault, Constance; Gandaglia, Giorgio; Tilki, Derya; EAU-YAU Prostate Cancer Working Group.

In: CANCERS, Vol. 14, No. 1, 147, 2022.

Research output: SCORING: Contribution to journal › SCORING: Review article › Research

Harvard

Kretschmer, A, van den Bergh, RCN, Martini, A, Marra, G, Valerio, M, Tsaur, I, Heidegger, I, Kasivisvanathan, V, Kesch, C, Preisser, F, Fankhauser, CD, Zattoni, F, Ceci, F, Olivier, J, Chiu, P, Puche-Sanz, I, Thibault, C, Gandaglia, G, Tilki, D & EAU-YAU Prostate Cancer Working Group 2022, 'Assessment of Health-Related Quality of Life in Patients with Advanced Prostate Cancer-Current State and Future Perspectives', CANCERS, vol. 14, no. 1, 147. https://doi.org/10.3390/cancers14010147

APA

Kretschmer, A., van den Bergh, R. C. N., Martini, A., Marra, G., Valerio, M., Tsaur, I., Heidegger, I., Kasivisvanathan, V., Kesch, C., Preisser, F., Fankhauser, C. D., Zattoni, F., Ceci, F., Olivier, J., Chiu, P., Puche-Sanz, I., Thibault, C., Gandaglia, G., Tilki, D., & EAU-YAU Prostate Cancer Working Group (2022). Assessment of Health-Related Quality of Life in Patients with Advanced Prostate Cancer-Current State and Future Perspectives. CANCERS, 14(1), [147]. https://doi.org/10.3390/cancers14010147

Vancouver

Kretschmer A, van den Bergh RCN, Martini A, Marra G, Valerio M, Tsaur I et al. Assessment of Health-Related Quality of Life in Patients with Advanced Prostate Cancer-Current State and Future Perspectives. CANCERS. 2022;14(1). 147. https://doi.org/10.3390/cancers14010147

Bibtex

@article{16e1fe3e37f94614b721a9fa23497e7e,
title = "Assessment of Health-Related Quality of Life in Patients with Advanced Prostate Cancer-Current State and Future Perspectives",
abstract = "With the therapeutic landscape of advanced prostate cancer rapidly evolving and oncological benefits being shown for a plethora of new agents and indications, health-related quality of life (HRQOL)-associated evidence is still subpar. In the current comprehensive review, we discuss the importance of HRQOL for patients with advanced PC (metastatic hormone-sensitive prostate cancer (mHSPC), metastatic castration-resistant prostate cancer (mCRPC) and non-metastatic castration-resistant prostate cancer (nmCRPC)), and present the most frequently used tools to evaluate HRQOL in recent randomized trials. Furthermore, we discuss the ease of use of these validated questionnaires for clinicians and try to focus on the suggested appropriate use in clinical practice, as well as potential strategies for improvement of HRQOL evaluation in these clinical scenarios of advanced prostate cancer.",
author = "Alexander Kretschmer and {van den Bergh}, {Roderick C N} and Alberto Martini and Giancarlo Marra and Massimo Valerio and Igor Tsaur and Isabel Heidegger and Veeru Kasivisvanathan and Claudia Kesch and Felix Preisser and Fankhauser, {Christian D} and Fabio Zattoni and Francesco Ceci and Jonathan Olivier and Peter Chiu and Ignacio Puche-Sanz and Constance Thibault and Giorgio Gandaglia and Derya Tilki and {EAU-YAU Prostate Cancer Working Group}",
year = "2022",
doi = "10.3390/cancers14010147",
language = "English",
volume = "14",
journal = "CANCERS",
issn = "2072-6694",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "1",

}

RIS

TY - JOUR

T1 - Assessment of Health-Related Quality of Life in Patients with Advanced Prostate Cancer-Current State and Future Perspectives

AU - Kretschmer, Alexander

AU - van den Bergh, Roderick C N

AU - Martini, Alberto

AU - Marra, Giancarlo

AU - Valerio, Massimo

AU - Tsaur, Igor

AU - Heidegger, Isabel

AU - Kasivisvanathan, Veeru

AU - Kesch, Claudia

AU - Preisser, Felix

AU - Fankhauser, Christian D

AU - Zattoni, Fabio

AU - Ceci, Francesco

AU - Olivier, Jonathan

AU - Chiu, Peter

AU - Puche-Sanz, Ignacio

AU - Thibault, Constance

AU - Gandaglia, Giorgio

AU - Tilki, Derya

AU - EAU-YAU Prostate Cancer Working Group

PY - 2022

Y1 - 2022

N2 - With the therapeutic landscape of advanced prostate cancer rapidly evolving and oncological benefits being shown for a plethora of new agents and indications, health-related quality of life (HRQOL)-associated evidence is still subpar. In the current comprehensive review, we discuss the importance of HRQOL for patients with advanced PC (metastatic hormone-sensitive prostate cancer (mHSPC), metastatic castration-resistant prostate cancer (mCRPC) and non-metastatic castration-resistant prostate cancer (nmCRPC)), and present the most frequently used tools to evaluate HRQOL in recent randomized trials. Furthermore, we discuss the ease of use of these validated questionnaires for clinicians and try to focus on the suggested appropriate use in clinical practice, as well as potential strategies for improvement of HRQOL evaluation in these clinical scenarios of advanced prostate cancer.

AB - With the therapeutic landscape of advanced prostate cancer rapidly evolving and oncological benefits being shown for a plethora of new agents and indications, health-related quality of life (HRQOL)-associated evidence is still subpar. In the current comprehensive review, we discuss the importance of HRQOL for patients with advanced PC (metastatic hormone-sensitive prostate cancer (mHSPC), metastatic castration-resistant prostate cancer (mCRPC) and non-metastatic castration-resistant prostate cancer (nmCRPC)), and present the most frequently used tools to evaluate HRQOL in recent randomized trials. Furthermore, we discuss the ease of use of these validated questionnaires for clinicians and try to focus on the suggested appropriate use in clinical practice, as well as potential strategies for improvement of HRQOL evaluation in these clinical scenarios of advanced prostate cancer.

U2 - 10.3390/cancers14010147

DO - 10.3390/cancers14010147

M3 - SCORING: Review article

C2 - 35008310

VL - 14

JO - CANCERS

JF - CANCERS

SN - 2072-6694

IS - 1

M1 - 147

ER -